1. Wei, Jinlian, Chen, Xin, Li, Yongyun, Xu, Xiaofang, Li, Jian. 2022. Cucurbitacin B-induced G2/M cell cycle arrest of conjunctival melanoma cells mediated by GRP78-FOXM1-KIF20A pathway. In Acta pharmaceutica Sinica. B, 12, 3861-3876. doi:10.1016/j.apsb.2022.05.021. https://pubmed.ncbi.nlm.nih.gov/36213538/
2. Chen, Shujia, Zhao, Lili, Liu, Jie, Wang, Fengmei, Li, Jia. 2024. Inhibition of KIF20A enhances the immunotherapeutic effect of hepatocellular carcinoma by enhancing c-Myc ubiquitination. In Cancer letters, 598, 217105. doi:10.1016/j.canlet.2024.217105. https://pubmed.ncbi.nlm.nih.gov/38971490/
3. Li, Lin, Lei, Qingsong, Zhang, Shujun, Kong, Lingna, Qin, Bo. 2017. Screening and identification of key biomarkers in hepatocellular carcinoma: Evidence from bioinformatic analysis. In Oncology reports, 38, 2607-2618. doi:10.3892/or.2017.5946. https://pubmed.ncbi.nlm.nih.gov/28901457/
4. Huang, Xuchen, Li, Sainan, Gao, Wei, Li, Ziyi, Geng, Cuizhi. 2023. KIF20A is a Prognostic Marker for Female Patients with Estrogen Receptor-Positive Breast Cancer and Receiving Tamoxifen as Adjuvant Endocrine Therapy. In International journal of general medicine, 16, 3623-3635. doi:10.2147/IJGM.S425918. https://pubmed.ncbi.nlm.nih.gov/37637711/
5. Su, Zhixiong, Zhong, Yaqi, He, Yufang, Wang, Lei, Liu, Zhihua. 2024. Bulk- and single cell-RNA sequencing reveal KIF20A as a key driver of hepatocellular carcinoma progression and immune evasion. In Frontiers in immunology, 15, 1469827. doi:10.3389/fimmu.2024.1469827. https://pubmed.ncbi.nlm.nih.gov/39555078/
智鼠故事 
